Caco-2 cells permeability evaluation of nifuroxazide derivatives with potential activity against methicillin-resistant Staphylococcus aureus (MRSA)

Abstract Throughout the period of evaluation and selection in drug development, the assessment of the permeability potential of a compound to achieve an efficient refinement of the molecular structure has been widely appraised by the transport of substances across cell monolayers. This study aims to...

Full description

Saved in:
Bibliographic Details
Published in:Drug development and industrial pharmacy Vol. 41; no. 7; pp. 1066 - 1072
Main Authors: B. Fernandes, Mariane, Gonçalves, José E., C. Tavares, Leoberto, Storpirtis, Sílvia
Format: Journal Article
Language:English
Published: England Informa Healthcare USA, Inc 01-07-2015
Informa Healthcare
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Abstract Throughout the period of evaluation and selection in drug development, the assessment of the permeability potential of a compound to achieve an efficient refinement of the molecular structure has been widely appraised by the transport of substances across cell monolayers. This study aims to develop in vitro assays through Caco-2 cells in order to analyze the permeability of 5-nitro-heterocyclic compounds analogues to nifuroxazide with antimicrobial activity, especially showing promising activity against multidrug-resistant Staphylococcus aureus (MRSA). Caco-2 cell monolayers cultivated for 21 days in Transwell® plates were used for the in vitro permeability assays. The quantification of the nifuroxazide derivatives in the basolateral chambers was performed by a validated high performance liquid chromatography with UV (HPLC-UV) method. Apparent permeability values (Papp) show that these compounds can be considered as new drug candidates with the potential to present high absorption in vivo, according to the classifications of Yee and Biganzoli. The thiophenic derivatives showed permeability values higher than the furanic ones, being AminoTIO the compound with the greatest potential for the development of a new drug against MRSA, since it showed the best cytotoxicity, permeability and solubility ratio among all the derivatives.
AbstractList Throughout the period of evaluation and selection in drug development, the assessment of the permeability potential of a compound to achieve an efficient refinement of the molecular structure has been widely appraised by the transport of substances across cell monolayers. This study aims to develop in vitro assays through Caco-2 cells in order to analyze the permeability of 5-nitro-heterocyclic compounds analogues to nifuroxazide with antimicrobial activity, especially showing promising activity against multidrug-resistant Staphylococcus aureus (MRSA). Caco-2 cell monolayers cultivated for 21 days in Transwell® plates were used for the in vitro permeability assays. The quantification of the nifuroxazide derivatives in the basolateral chambers was performed by a validated high performance liquid chromatography with UV (HPLC-UV) method. Apparent permeability values (Papp) show that these compounds can be considered as new drug candidates with the potential to present high absorption in vivo, according to the classifications of Yee and Biganzoli. The thiophenic derivatives showed permeability values higher than the furanic ones, being AminoTIO the compound with the greatest potential for the development of a new drug against MRSA, since it showed the best cytotoxicity, permeability and solubility ratio among all the derivatives.
Abstract Throughout the period of evaluation and selection in drug development, the assessment of the permeability potential of a compound to achieve an efficient refinement of the molecular structure has been widely appraised by the transport of substances across cell monolayers. This study aims to develop in vitro assays through Caco-2 cells in order to analyze the permeability of 5-nitro-heterocyclic compounds analogues to nifuroxazide with antimicrobial activity, especially showing promising activity against multidrug-resistant Staphylococcus aureus (MRSA). Caco-2 cell monolayers cultivated for 21 days in Transwell® plates were used for the in vitro permeability assays. The quantification of the nifuroxazide derivatives in the basolateral chambers was performed by a validated high performance liquid chromatography with UV (HPLC-UV) method. Apparent permeability values (Papp) show that these compounds can be considered as new drug candidates with the potential to present high absorption in vivo, according to the classifications of Yee and Biganzoli. The thiophenic derivatives showed permeability values higher than the furanic ones, being AminoTIO the compound with the greatest potential for the development of a new drug against MRSA, since it showed the best cytotoxicity, permeability and solubility ratio among all the derivatives.
Author Gonçalves, José E.
C. Tavares, Leoberto
Storpirtis, Sílvia
B. Fernandes, Mariane
Author_xml – sequence: 1
  givenname: Mariane
  surname: B. Fernandes
  fullname: B. Fernandes, Mariane
  email: mmarianebf@gmail.com, mmarianebf@gmail.com
  organization: Pharmacy Department, Pharmaceutical Sciences Faculty, University of São Paulo
– sequence: 2
  givenname: José E.
  surname: Gonçalves
  fullname: Gonçalves, José E.
  email: mmarianebf@gmail.com, mmarianebf@gmail.com
  organization: Pharmacy Department, Pharmaceutical Sciences Faculty, University of São Paulo
– sequence: 3
  givenname: Leoberto
  surname: C. Tavares
  fullname: C. Tavares, Leoberto
  email: mmarianebf@gmail.com, mmarianebf@gmail.com
  organization: Chemical and Pharmaceutical Technology Department, Pharmaceutical Sciences Faculty, University of São Paulo
– sequence: 4
  givenname: Sílvia
  surname: Storpirtis
  fullname: Storpirtis, Sílvia
  email: mmarianebf@gmail.com, mmarianebf@gmail.com
  organization: Pharmacy Department, Pharmaceutical Sciences Faculty, University of São Paulo
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24918173$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1u1DAUhS1URKeFN0DIy3aRwXbiJN6AqhF_UhEShXV047lmXDl2sJ0pw2vwwiSaFolNV1eyv3Pu1Tln5MQHj4S85GxdcqZes7IuFavkWjBerZWQiqsnZMWlYIVsanFCVgtSLMwpOUvpljEulJTPyKmoFG95U67Inw3oUAiq0blER4wDQm-dzQeKe3ATZBs8DYZ6a6YYfsFvu0W6xWj389ceE72zeUfHkNFnC46Cnp8XOfwA61OmA-ad1dY564uIyaYMPtObDOPu4IIOWk-JwhRxHhefv95cXT4nTw24hC_u5zn5_v7dt83H4vrLh0-bq-tCV7zNRVuLSoIUxqhW8FYiR63qtsW6EWWtVW-YMXMqvWgFa5q6lwb7ptkybkRf1VCek4uj7xjDzwlT7gabliDAY5hSx2vFpap4zWa0OqI6hpQimm6MdoB46Djrljq6hzq6pY7uWMcse3W_YeoH3P4TPeQ_A2-PgPUmxAHuQnTbLsOcTDQRvLZpsX90xZv_HHYILu80ROxuwxT9HODjN_4Fr3Sx3w
CitedBy_id crossref_primary_10_1016_j_molliq_2021_116911
crossref_primary_10_1002_slct_202305142
crossref_primary_10_1007_s10534_018_0160_0
crossref_primary_10_1016_j_drudis_2019_06_017
crossref_primary_10_1016_j_ejps_2019_105092
crossref_primary_10_1016_j_jddst_2019_101413
Cites_doi 10.1002/bdd.2510070504
10.1016/S0928-0987(03)00146-5
10.1021/js9803205
10.3109/03639045.2012.746362
10.1023/A:1018961828510
10.1128/AAC.31.9.1429
10.1099/00222615-37-3-221
10.3109/03639045.2012.723218
10.1016/j.bmc.2009.03.011
10.1023/A:1020483911355
10.1007/978-1-4899-1863-5_3
10.1023/A:1012102522787
10.5694/j.1326-5377.2004.tb06444.x
10.1023/A:1018990602102
10.1016/S0014-827X(99)00069-5
10.1016/S0378-5173(98)00330-5
10.1016/j.bmc.2007.03.068
10.1023/A:1012155124489
10.1002/jps.20149
10.1016/j.mib.2004.08.007
10.1016/S0378-5173(00)00334-3
10.1016/S1056-8719(00)00113-1
10.1007/s11095-004-9004-4
10.1002/jps.2600790710
10.1208/s12248-010-9176-2
10.3109/03639045.2014.900077
10.1124/dmd.110.034629
10.1016/j.febslet.2007.05.051
10.1023/A:1018937416447
10.1016/S1359-6446(04)03354-9
10.1023/A:1007585105753
10.1016/j.tiv.2012.01.018
10.1016/0006-291X(91)91647-U
ContentType Journal Article
Copyright 2014 Informa Healthcare USA, Inc. All rights reserved: reproduction in whole or part not permitted 2014
Copyright_xml – notice: 2014 Informa Healthcare USA, Inc. All rights reserved: reproduction in whole or part not permitted 2014
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.3109/03639045.2014.925919
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE

Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1520-5762
EndPage 1072
ExternalDocumentID 10_3109_03639045_2014_925919
24918173
925919
Genre Research Articles
Journal Article
Comparative Study
GroupedDBID ---
.GJ
00X
03L
0BK
0R~
29G
36B
4.4
53G
5GY
5VS
8VB
AACCU
AAJNR
AALIY
AALUX
AAMIU
AAPUL
AAPXX
AAQRR
ABBKH
ABCRQ
ABEIZ
ABLKL
ABUPF
ACENM
ACFUF
ACGEJ
ACGFS
ACLSK
ADCVX
ADFCX
ADRBQ
ADXPE
AECIN
AEMOZ
AENEX
AEOZL
AEYQI
AFAUU
AFKVX
AFOSN
AFQCT
AFWLO
AGAFX
AGDLA
AGFJD
AGRBW
AGYJP
AIJEM
AIRBT
AJEBJ
AJWEG
AJXHO
AKBVH
AKVCP
ALIIL
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AWYRJ
BABNJ
BLEHA
BOHLJ
BVLLS
CAG
CCCUG
COF
CS3
DEIEU
DKSSO
DLVIE
DTRLO
DU5
DZHFC
EBC
EBD
EBO
EBR
EBS
EBU
EHE
EJD
EMB
EMK
EMOBN
EPL
F5P
H13
HZ~
IPNFZ
J.N
JFOCU
KRBQP
KSSTO
KUULJ
KWAYT
KYCEM
LJTGL
LSO
M44
M4Z
MK0
O9-
QRXOQ
QWB
RNANH
RVRKI
SV3
TFDNU
TFL
TFW
TH9
UHWXJ
V1S
Y6R
ZL0
~1N
ABJNI
ABLIJ
ABXYU
ACIEZ
ALYBC
CGR
CUY
CVF
ECM
EIF
K1G
NPM
NUSFT
TBQAZ
TDBHL
TERGH
TUROJ
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c418t-86245a52ff982185e1ec9688e67236c9bf0ff591b2820776b5feb77d01f2b46a3
ISSN 0363-9045
IngestDate Fri Oct 25 22:35:02 EDT 2024
Thu Nov 21 22:58:09 EST 2024
Tue Oct 15 23:55:29 EDT 2024
Tue Jun 13 19:51:27 EDT 2023
Tue Jul 04 19:21:04 EDT 2023
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords biopharmacy
drug development
5-Nitro-heterocyclic
intestinal absorption
anti-infectives
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c418t-86245a52ff982185e1ec9688e67236c9bf0ff591b2820776b5feb77d01f2b46a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 24918173
PQID 1691594160
PQPubID 23479
PageCount 7
ParticipantIDs crossref_primary_10_3109_03639045_2014_925919
informaworld_taylorfrancis_310_3109_03639045_2014_925919
proquest_miscellaneous_1691594160
pubmed_primary_24918173
informahealthcare_journals_10_3109_03639045_2014_925919
PublicationCentury 2000
PublicationDate 2015-07-01
PublicationDateYYYYMMDD 2015-07-01
PublicationDate_xml – month: 07
  year: 2015
  text: 2015-07-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Drug development and industrial pharmacy
PublicationTitleAlternate Drug Dev Ind Pharm
PublicationYear 2015
Publisher Informa Healthcare USA, Inc
Informa Healthcare
Publisher_xml – name: Informa Healthcare USA, Inc
– name: Informa Healthcare
References CIT0030
Charles PGP (CIT0003) 2004; 181
CIT0010
CIT0032
CIT0031
CIT0012
CIT0034
CIT0011
CIT0033
Gonçalves JE (CIT0017) 2009
Shah RR (CIT0026) 1989; 8
Rubas W (CIT0015) 1995; 5
Buzard JA (CIT0025) 1961; 131
CIT0014
CIT0036
CIT0013
CIT0035
CIT0016
CIT0038
CIT0037
CIT0018
CIT0039
CIT0019
Ferraz HG (CIT0043) 2009
CIT0041
CIT0040
CIT0021
CIT0020
CIT0042
CIT0023
Nakao M (CIT0001) 2006; 12
CIT0002
CIT0024
CIT0005
CIT0027
CIT0004
CIT0007
CIT0006
CIT0028
CIT0009
CIT0008
References_xml – ident: CIT0024
  doi: 10.1002/bdd.2510070504
– ident: CIT0032
  doi: 10.1016/S0928-0987(03)00146-5
– ident: CIT0010
  doi: 10.1021/js9803205
– ident: CIT0042
  doi: 10.3109/03639045.2012.746362
– ident: CIT0013
  doi: 10.1023/A:1018961828510
– ident: CIT0020
  doi: 10.1128/AAC.31.9.1429
– ident: CIT0021
  doi: 10.1099/00222615-37-3-221
– ident: CIT0040
  doi: 10.3109/03639045.2012.723218
– ident: CIT0004
  doi: 10.1016/j.bmc.2009.03.011
– volume: 8
  start-page: 183
  year: 1989
  ident: CIT0026
  publication-title: Adverse Drug React Acute Poisoning Rev
  contributor:
    fullname: Shah RR
– ident: CIT0036
  doi: 10.1023/A:1020483911355
– volume: 5
  start-page: 93
  year: 1995
  ident: CIT0015
  publication-title: S.T.p. Pharma Sci
  contributor:
    fullname: Rubas W
– ident: CIT0031
  doi: 10.1007/978-1-4899-1863-5_3
– ident: CIT0018
  doi: 10.1023/A:1012102522787
– volume: 181
  start-page: 549
  year: 2004
  ident: CIT0003
  publication-title: Med J Aust
  doi: 10.5694/j.1326-5377.2004.tb06444.x
  contributor:
    fullname: Charles PGP
– ident: CIT0014
  doi: 10.1023/A:1018990602102
– ident: CIT0019
  doi: 10.1016/S0014-827X(99)00069-5
– ident: CIT0016
  doi: 10.1016/S0378-5173(98)00330-5
– ident: CIT0023
– ident: CIT0005
  doi: 10.1016/j.bmc.2007.03.068
– ident: CIT0007
  doi: 10.1023/A:1012155124489
– ident: CIT0035
– ident: CIT0038
  doi: 10.1002/jps.20149
– ident: CIT0002
  doi: 10.1016/j.mib.2004.08.007
– ident: CIT0011
  doi: 10.1016/S0378-5173(00)00334-3
– ident: CIT0006
  doi: 10.1016/S1056-8719(00)00113-1
– ident: CIT0039
  doi: 10.1007/s11095-004-9004-4
– ident: CIT0030
  doi: 10.1002/jps.2600790710
– ident: CIT0037
  doi: 10.1208/s12248-010-9176-2
– start-page: 204
  volume-title: Biofarmacotécnica – série ciências farmacêuticas
  year: 2009
  ident: CIT0017
  contributor:
    fullname: Gonçalves JE
– ident: CIT0041
  doi: 10.3109/03639045.2014.900077
– volume: 12
  start-page: 1
  year: 2006
  ident: CIT0001
  publication-title: Kaw J Med Welfare
  contributor:
    fullname: Nakao M
– ident: CIT0027
  doi: 10.1124/dmd.110.034629
– ident: CIT0033
  doi: 10.1016/j.febslet.2007.05.051
– ident: CIT0012
  doi: 10.1023/A:1018937416447
– start-page: 66
  volume-title: Biofarmacotécnica – série ciências farmacêuticas
  year: 2009
  ident: CIT0043
  contributor:
    fullname: Ferraz HG
– ident: CIT0009
  doi: 10.1016/S1359-6446(04)03354-9
– volume: 131
  start-page: 38
  year: 1961
  ident: CIT0025
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Buzard JA
– ident: CIT0034
  doi: 10.1023/A:1007585105753
– ident: CIT0028
  doi: 10.1016/j.tiv.2012.01.018
– ident: CIT0008
  doi: 10.1016/0006-291X(91)91647-U
SSID ssj0012955
Score 2.184722
Snippet Abstract Throughout the period of evaluation and selection in drug development, the assessment of the permeability potential of a compound to achieve an...
Throughout the period of evaluation and selection in drug development, the assessment of the permeability potential of a compound to achieve an efficient...
SourceID proquest
crossref
pubmed
informaworld
informahealthcare
SourceType Aggregation Database
Index Database
Publisher
StartPage 1066
SubjectTerms 5-Nitro-heterocyclic
Anti-Infective Agents - administration & dosage
Anti-Infective Agents - pharmacokinetics
Anti-Infective Agents - pharmacology
anti-infectives
biopharmacy
Caco-2 Cells
Chromatography, High Pressure Liquid
drug development
Humans
Hydroxybenzoates - administration & dosage
Hydroxybenzoates - pharmacokinetics
Hydroxybenzoates - pharmacology
intestinal absorption
Methicillin-Resistant Staphylococcus aureus - drug effects
Nitrofurans - administration & dosage
Nitrofurans - pharmacokinetics
Nitrofurans - pharmacology
Permeability
Solubility
Spectrophotometry, Ultraviolet
Title Caco-2 cells permeability evaluation of nifuroxazide derivatives with potential activity against methicillin-resistant Staphylococcus aureus (MRSA)
URI https://www.tandfonline.com/doi/abs/10.3109/03639045.2014.925919
https://www.ncbi.nlm.nih.gov/pubmed/24918173
https://search.proquest.com/docview/1691594160
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3JbtswECXi5NJLke7uBhYoghaOXJvaj4btNpcEQeMCvQmURKYCUsuQJaPpb_SHO0NSi1N3BXoRDBk0Zb3H4cxwFkJewh6fusJOLd-LheWAxm3xQKYWC9LQEyxxY9UO6OTCP_sYzObOfK9Xt7ds7_1XpOEeYI2Zs3-BdvOjcAM-A-ZwBdTh-ke4T0HEWWyADvk1FiX-LHQl7utOYW8VvZHJqsi_8K9ZiqlThepyhiVolWd2lZcYRoSFBBLTX4Jf8gx0SdVzOkvQTbO0wFZH_XNZotIKgMHOmCdJtR7wqhCVcuievr-Y1O4GowTPiuqyztZqYtyztofISpfTblMthoPa3b02-UVA6oaR70B7xeN-n19tRH2soQMABvNhc8gyHCz4BrOtlCtCqIjyvHEwlXmxyrAztXIHq9Gzq03Gu16RsdtE0BpLeSuXC4PoOnIVj67Dka5iORRG7oMV7d7YGHRFLrMA_I6UBzPa62gMYEGzXbuRrYu54nw4HcYROsMQ7E2zSWzX-dZf9MgBA5EJEvtgMp2fnTYnYixUHXybh9dpoDjFm10TbKlZh6YI76fmbdwozPtz80qpWYtDctvYR3SiiX2H7InlXXJ0bhhxTBdtvuD6mB7R87b0-vU98k2znyr20y77act-mkvaZT_tsJ8i-2nDflqznxr2053sp9vsp5r99BVy__V98uHtfDE9sUzbEStxxkFpYcqUy10mZRiAAuyKsUhCLwiE5zPbS8JYjqSEdxwz0J59kHGuFLHvp6OxZLHjcfsB2V_mS_GIUDCn7GTEQCWXgZPYNg-8kNuB5_joR-Bxn1g1StFKV5eJwCpHVKMa1QhRjTSqfeL_AGVkhM_6NyODLuBRqfyBUjfvwWG_GvqiJkcEew8iCGs8r2BCLwRrCMT9qE8eatY0f4M5IRgPvv343yd-Qm61S_sp2S-LSjwjvXVaPTer4zsLJQYP
link.rule.ids 315,782,786,27933,27934,59868,60657,61275,61456
linkProvider Taylor & Francis
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELage4DLsrzL00hoBdJ6N83DsY9V6aqIbbVii8TNchwbekmqJllR_gZ_mJk4bXloQUKcEilyHGdm7G_smW8IeQlrfJ7YKGcpzyyLAXEzLVzOQpFLbkOTZG05oMlFOvso3oyRJme4yYXBsEr0oZ0nimjnajRu3Iw-aV3MQJ7g4aMELIKRWfGxBASPxJ97SDUuemRvOBrPptujhFC2pU_bA0ts5PPnrnzPT-vTQcde-nkbi_ULo-nVuLRdn05v_YeRHZD9DpzSodem2-SaLe6Qw3PPbr0-ovNdslZ1RA_p-Y73en2XfBvBLQspngVUdAlTvvUk4Gu64xSnpaPFwjWr8ov-usgtzcEELlv28YripjBdljVGMMF3YM4Flrag-pNeAIylWO56YXCHqGArWyH0LWoKeBl0BRbl0pimorpZWbi8mr6_GL6-Rz6cjuejCetqPjATD0TNMF8l0UnonBSAPhI7sEZyISxPw4gbmbnAOfgrGbiKyESUJc5maZoHAxdmMdfRfdIrysI-JBSwbGSCEPCQE7GJIi241JHgcYpOnM76hG0krZae2kOBS4RyUBs5KJSD8nLok_Q3dVCdxVd_aSl-VBpVt5sxzldOwWZ_avpio2AKDB8lqAtbNtAhlwBFwdaCPnngNW87DPCpAbml0aN_7_g5uTGZT8_U2dvZu8fkJjxJfJTyE9KrV419Sq5XefOss7bvvugnbQ
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdgkxAvY3wXGBgJTSDNW5oPx36sulZDsKpiQ-ItcvwBfUmqJpnW_Rv8w9zFaTtAAwmeEilyHOfu7N_Zd78j5A2s8SaxkWEpzy2LAXEzJZxhoTCS21AneVsO6OQsnXwRxyOkyVln8WNYJfrQzhNFtHM1GvfcuKPWwwzkEZ49SoAiGJgVH0oA8Mj7uQ1QPAH3a3swHE1O1ycJoWwrn7bnldjIp8_d-J6flqfdjrz02zoU6xdC05thabs8je_9_8B2yU4HTenA69J9cssWD8j-1HNbLw_o-SZVqzqg-3S6Yb1ePiTfh3DLQoonARWdw4RvPQX4km4YxWnpaDFzzaK8VFczY6kBA7houccrilvCdF7WGL8E34EZF1jYgqqvagYglmKx65nG_aGCLWyFwLeoKaBl0BRYkkutm4qqZmHh8vb009ng3SPyeTw6H56wruID03Ff1AyzVRKVhM5JAdgjsX2rJRfC8jSMuJa5C5yDv5KDo4g8RHnibJ6mJui7MI-5ih6TraIs7FNCAclGOggBDTkR6yhSgksVCR6n6MKpvEfYStDZ3BN7ZOAQoRyylRwylEPm5dAj6W_akHX2Xv2lpbiuM1ndbsU4XzcFm_2p6euVfmVg9ihBVdiygQ65BCAKlhb0yBOveOthgEcNuC2Nnv17x6_InenxOPv4fvLhObkLDxIfovyCbNWLxu6R25VpXna29gP1UiYR
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Caco-2+cells+permeability+evaluation+of+nifuroxazide+derivatives+with+potential+activity+against+methicillin-resistant+Staphylococcus+aureus+%28MRSA%29&rft.jtitle=Drug+development+and+industrial+pharmacy&rft.au=B.+Fernandes%2C+Mariane&rft.au=Gon%C3%A7alves%2C+Jos%C3%A9+E.&rft.au=C.+Tavares%2C+Leoberto&rft.au=Storpirtis%2C+S%C3%ADlvia&rft.date=2015-07-01&rft.pub=Informa+Healthcare&rft.issn=0363-9045&rft.eissn=1520-5762&rft.volume=41&rft.issue=7&rft.spage=1066&rft.epage=1072&rft_id=info:doi/10.3109%2F03639045.2014.925919&rft.externalDocID=925919
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0363-9045&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0363-9045&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0363-9045&client=summon